Lv5
1062 积分 2024-07-04 加入
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
1天前
待确认
Targeting claudins in cancer
11天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
11天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
11天前
已完结
Erdafitinib in Patients with FGFR- Altered Advanced or Metastatic Cholangiocarcinoma
16天前
已完结
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
16天前
已完结
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
16天前
已完结
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
18天前
已完结
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
18天前
已完结
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
18天前
已完结
皖公网安备34019202002308
